### SUPPLEMENT DATED 9 MARCH 2018 TO THE BASE PROSPECTUS DATED 5 DECEMBER 2017



#### Santander UK plc

(incorporated in England and Wales with limited liability, registered number 2294747)

This supplement (the "**Supplement**", which definition shall also include all information incorporated by reference herein) is prepared as a supplement to, and must be read in conjunction with the Base Prospectus dated 5 December 2017 as supplemented on 12 February 2018 relating to the Notes and Certificates Programme (the "**Base Prospectus**").

This Supplement together with the Base Prospectus constitutes a base prospectus for the purposes of Article 5.4 of Directive 2003/71/EC, as amended (which includes the amendments made by Directive 2010/73/EU to the extent that such amendments have been implemented in a relevant Member State of the European Economic Area) (the "**Prospectus Directive**")). Terms defined in the Base Prospectus have the same meaning when used in this Supplement.

This Supplement is supplemental to, and should be read in conjunction with the Base Prospectus and any other supplements to the Base Prospectus prepared by Santander UK plc as issuer under the Notes and Certificates Programme (the "**Issuer**").

This Supplement has been approved by the Central Bank of Ireland (the "**Central Bank**") as Irish competent authority under the Prospectus Directive. The Central Bank only approves this Supplement as meeting the requirements imposed under Irish and EU law pursuant to the Prospectus Directive. Such approval relates only to the Securities which are to be admitted to trading on the regulated market of the Irish Stock Exchange or other regulated markets for the purposes of Directive 2014/65/EU (the "**Markets in Financial Instruments Directive**") or which are to be offered to the public in a Member State of the European Economic Area.

The Issuer accepts responsibility for the information contained in this Supplement. To the best of the knowledge of the Issuer (having taken all reasonable care to ensure that such is the case) the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

The Issuer has requested the Central Bank of Ireland, in accordance with Article 18 of the Prospectus Directive, provide to the United Kingdom Financial Conduct Authority, in its capacity as United Kingdom competent authority, a certificate of approval attesting that this Supplement has been drawn up in accordance with the Prospectus Directive.

This Supplement has been prepared for the purpose of: (i) incorporating by reference into the Base Prospectus certain sections of the Issuer's annual report for the year ended 31 December 2017 and the related glossary (each as described in Schedule 1 hereto) and (ii) updating the Summary of the Programme contained in the Base Prospectus (as described in Schedule 2 hereto). To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference in the Base Prospectus by this Supplement and (b) any other statement in or incorporated by reference in the Base Prospectus prior to the date of this Supplement, the statement referred to in (a) above will prevail.

If any documents which are incorporated by reference themselves incorporate any information or other documents therein, either expressly or implicitly, such information or other documents will not form part of

this Supplement or the Base Prospectus for the purposes of the Prospectus Directive except where such information or other documents are specifically incorporated by reference or attached to this Supplement.

Any non-incorporated parts of a document referred to herein are either deemed not relevant for an investor or are otherwise covered elsewhere in the Base Prospectus to which this Supplement relates.

Save as disclosed in this Supplement, no significant new factor, material mistake or inaccuracy relating to information included in the Base Prospectus has arisen or been noted, as the case may be, since the publication of the Base Prospectus.

There has been no significant change in the financial position of Santander UK plc and its subsidiaries since 31 December 2017 (being the date to which the most recent financial information was prepared).

In accordance with Article 16.2 of the Prospectus Directive, investors who have agreed to purchase or subscribe for securities before this Supplement is published have the right, exercisable before the end of the period of two working days beginning with the working day after the date on which this Supplement was published, to withdraw their acceptances by sending a written notice of withdrawal (which must include the full name and address of the person or entity wishing to exercise such statutory withdrawal right and identify the transferable securities to which that statutory withdrawal right relates) by electronic mail to structurednotesafm@santander.co.uk. The final date for any such withdrawal is 13 March 2018.

#### SCHEDULE 1

#### DOCUMENTS INCORPORATED BY REFERENCE

The Issuer has published its annual report for the year ended 31 December 2017 (the "**2017 Annual Report**"), which contains the following information which is hereby incorporated in and forms part of the Base Prospectus:

- (i) the audited consolidated financial statements of the Issuer for the financial year ended 31 December 2017 and auditors' report thereon which appear on pages 136 151 (inclusive) of the 2017 Annual Report; and
- (ii) the risk review appearing on pages 57 135 (inclusive) of the 2017 Annual Report, with the exception of any section which is marked as unaudited.

The relevant sections of the 2017 Annual Report listed above are available for viewing at: <u>https://www.santander.co.uk/csdlvlr/BlobServer?blobtable=MungoBlobs&blobkey=id&blobcol=urldata&blobtable=application%2Fpdf&blobheadervalue1=inline%3Bfilename%3DSantander+UK+plc+2017+Annual+Report+-+OpCo.pdf&blobwhere=1314024777754&blobheadername1=Content-Disposition.</u>

The glossary relating to the 2017 Annual Report is hereby incorporated in and forms part of the Base Prospectus and is available for viewing at:

 $\label{eq:https://www.santander.co.uk/csdlvlr/BlobServer?blobtable=MungoBlobs&blobkey=id&blobcol=urldata&blobheader=application%2Fpdf&blobheadervalue1=inline%3Bfilename%3DSantander+UK+2017+glossary.pdf&blobheadername1=Content-Disposition .$ 

# **SCHEDULE 2**

## SUPPLEMENT TO THE SUMMARY

The Summary contained in the Base Prospectus is hereby amended by deletion of Element B.12 and its replacement with the following:

		1 1.1 / 1
The audited consolidated balance sheet as at 31 December		
statement for each of the years ended 31 December 2017 and	1 31 December 2016 have been extracted v	without any adju
from, and should be read in conjunction with the Issuer's conso	lidated financial statements in respect of the	ose dates and per
Consolidated balance sheet (extract from Santander UK plc's Annual Report for the year ended 31 December 2017		
	31 December 2017	31 December
	£m	
Assets		
Cash and balances at central banks	32,771	
Trading assets	30,555	
Derivative financial instruments	19,942	
Financial assets designated at fair value	2,096	
Loans and advances to banks	5,927	
Loans and advances to customers	199,490	1
Financial investments	17,611	
Interests in other entities	73	
Intangible assets	1,742	
Property, plant and equipment	1,598	
Retirement benefit assets	449	
Other assets	2,511	
Total assets	314,765	
Liabilities		
Deposits by banks	13,784	
Deposits by customers	183,648	]
Trading liabilities	31,109	
Derivative financial instruments	17,613	
Financial liabilities designated at fair value	2,315	
Debt securities in issue	42,633	
Subordinated liabilities	3,793	
Other liabilities	2,730	
Provisions	558	
Current tax liabilities	3	
Deferred tax liabilities	88	
Retirement benefit obligations	286	
Total liabilities	298,560	2
Equity	2.110	
Share capital	3,119	
Share premium	5,620	
Other equity instruments	2,281	
Retained earnings	4,732	
Other reserves	301	
Total shareholders' equity	16,053	
Non-controlling interests	152	
Total equity	16,205	
Total liabilities and equity	314,765	

	31 December 2017	31 December 2016	
	£m	£m	
Interest and similar income	5,905	6,467	
Interest expense and similar charges	(2,102)	(2,885)	
Net interest income	3,803	3,582	
Fee and commission income	1,222	1,188	
Fee and commission expense	(415)	(418)	
Net fee and commission income	807	770	
Net trading and other income	302	443	
Total operating income	4,912	4,795	
Operating expenses before impairment losses, provisions and charges	(2,499)	(2,414	
Impairment losses on loans and advances	(203)	(67	
Provisions for other liabilities and charges	(393)	(397)	
Total operating impairment losses, provisions and charges	(596)	(464)	
Profit before tax	1,817	1,917	
Tax on profit	(561)	(598	
Profit after tax for the year	1,256	1,319	
Attributable to:			
Equity holders of the parent	1,235	1,292	
Non-controlling interests	21	27	